Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Docaravimab

😃Good
Catalog No. T77161Cas No. 2247196-23-0

Docaravimab, an antibody designed to target the G-III epitope within the ectodomain of the Evelyn-Rockitniki-Abelseth (ERA) glycoprotein, is utilized in rabies research [1].

Docaravimab

Docaravimab

😃Good
Catalog No. T77161Cas No. 2247196-23-0
Docaravimab, an antibody designed to target the G-III epitope within the ectodomain of the Evelyn-Rockitniki-Abelseth (ERA) glycoprotein, is utilized in rabies research [1].
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
5 mgInquiryInquiryInquiry
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
Docaravimab, an antibody designed to target the G-III epitope within the ectodomain of the Evelyn-Rockitniki-Abelseth (ERA) glycoprotein, is utilized in rabies research [1].
Reactivity
Human
Application
FACS
Functional assay
Antibody Type
Monoclonal
Endotoxin< 1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
TargetERA
Chemical Properties
Cas No.2247196-23-0
Storage & Solubility Information
Storage-20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Docaravimab | purchase Docaravimab | Docaravimab cost | order Docaravimab